Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017
Added 4 days ago Drug news
FDA approves Mvasi (bevacizumab-awwb) biosimilar for non-small cell lung cancer, for metastatic colorectal cancer, glioblastoma, metastatic renal cell carcinoma and carcinoma of the cervix.- Amgen and Allergan.
Amgen and Allergan announced that the FDA has approved Mvasi (bevacizumab-awwb) for all eligible indications of the reference product, Avastin...
Added 10 days ago Drug news
Phase III CheckMate -214 study of Opdivo plus Yervoy (nivolumab + ipilimumab) in untreated advanced or metastatic renal cell carcinoma meets endpoint and advisory committee recommends halting study.- BMS.
Bristol-Myers Squibb announced that a Phase III CheckMate -214 study evaluating Opdivo plus Yervoy (nivolumab + ipilimumab) in patients with...
Added 18 days ago Drug news
European Commission approves Fotivda (tivozanib) for the treatment of patients with advanced renal cell carcinoma.-Aveo Oncology + EUSA Pharma.
Aveo Oncology has announced that the European Commission (EC) has approved Fotivda (tivozanib) for the treatment of adult patients with...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists...
Added 1 year ago
The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...
Added 3 years ago
Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC.
Added 4 months ago
Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
Introduction: In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited.
Added 5 months ago
Clear cell renal cell carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL loss drives tumor angiogenesis and accounts for the clinical activity ...
Added 5 months ago
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.
Added 4 years ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.